Sign In
Buy SNDX
$19.32
+0.320 (+1.68%)
At Close: Jun 22, 2026
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced
08:57am, Thursday, 11'th Jun 2026
Syndax has transitioned into a two-product commercial oncology company with growing revenue and strong cash reserves. Revuforj and Niktimvo drive SNDX's revenue, with Q1 2026 net sales exceeding $100M
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
07:03am, Thursday, 11'th Jun 2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across sub
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
01:12pm, Wednesday, 10'th Jun 2026
Syndax Pharmaceuticals, Inc. (SNDX) Shareholder/Analyst Call Prepared Remarks Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
04:28pm, Monday, 08'th Jun 2026
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
07:00am, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
04:01pm, Tuesday, 02'nd Jun 2026
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 9
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
07:00am, Monday, 01'st Jun 2026
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
05:01pm, Thursday, 21'st May 2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
Syndax Announces Participation in Upcoming Investor Conferences
07:00am, Wednesday, 20'th May 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Me
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
10:31am, Tuesday, 12'th May 2026
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerab
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 06'th May 2026
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 202
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
10:51pm, Thursday, 30'th Apr 2026
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
06:30pm, Thursday, 30'th Apr 2026
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.98 per share a year ago.
